AGY
NEUTRALAllergy Therapeutics Issues Warrants to Lenders
The biotechnology company has issued warrants to lenders as part of a loan facility agreement.
Allergy Therapeutics
8.12GBX
-1.55%
Market Cap
387.15M
Volume
109.84k
26% of avg
P/E Ratio
-0.20
EPS (TTM)
-0.4
Beta
1.01
Day Range
7.70p - 8.25p
52 Week Range
3.80p8.12p8.30p
8.12p
Upcoming Events
AGY
NEUTRALAllergy Therapeutics Shares Research Findings at EAACI 2025 Congress
The biotechnology company will share key scientific findings from its research portfolio at the EAACI 2025 Congress, including preliminary clinical proof of concept for its peanut allergy vaccine candidate and data on its Grass MATA MPL immunotherapy.
AGY
NEUTRALAllergy Therapeutics Announces Winner of EAACI Early Career Research Award
The biotechnology company announces the winner of a research award in collaboration with the European Academy of Allergy and Clinical Immunology.
AGY
NEUTRALAllergy Therapeutics Reports Improved H1 Results and Clinical Progress
The biotechnology firm reported improved H1 results with revenue growth and reduced losses. Clinical progress in key allergy treatments was highlighted, but ongoing funding needs remain a concern.
AGY
NEUTRALAllergy Therapeutics Advances Peanut Allergy Vaccine Candidate to Final Phase of Clinical Trial
The biotechnology company specialising in allergy immunotherapies has advanced its innovative peanut allergy vaccine candidate to the final phase of a clinical trial, with healthy volunteers receiving the highest doses and no safety signals observed.
AGY
NEUTRALAllergy Therapeutics Grants New Executive Incentive Awards
The biotechnology company has granted new long-term incentive awards to its senior executives and share options to all other employees.
AGY
NEUTRALAllergy Therapeutics to Present at 2025 AAAAI / WAO Joint Congress
The biotechnology company will be sharing key scientific findings from its pollen and food-allergy research portfolio at the upcoming medical conference.
AGY
GOODAllergy Therapeutics Announces Positive Phase III Data for Grass MATA MPL
The biotechnology company announces positive Phase III trial results for its grass pollen allergy treatment, demonstrating significant efficacy improvements over placebo.
AGY
NEUTRALAllergy Therapeutics Grants Options to Management Team
The biotechnology company has granted share options to key members of its management team, aligning their interests with shareholders.
AGY
GOODAllergy Therapeutics reports revenue growth in first half
The biotechnology company reports revenue growth in the first half, with a recovery in manufacturing capacity and strengthened cash position following new financing facilities.